Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Maha Hussain(Northwestern University), Ian M. Thompson(The University of Texas at San Antonio Health Science Center), Donna L. Berry(University of Washington), E. David Crawford(Virginia Commonwealth University), Carol M. Moinpour(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Catherine M. Tangen(American Urological Association), Glenn Liu(University of Wisconsin Carbone Cancer Center), David I. Quinn(USC Norris Comprehensive Cancer Center), Bryan Donnelly, Benjamin Ely(SWOG Cancer Research Network), Derek Raghavan(United States Department of Veterans Affairs), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), George Wilding(The University of Texas MD Anderson Cancer Center), Ulka N. Vaishampayan(University of Michigan), Stephen M. Prescott(MACOM (United States)), Peter Venner(Cancer Institute (WIA)), Paul F. Schellhammer(Eastern Virginia Medical School), S.K. Sundaram(Mid Yorkshire Hospitals NHS Trust), Celestia S. Higano(University of British Columbia), Nancy A. Dawson(University of Maryland, Baltimore), Eric J. Small(CancerCare Manitoba)
Cited by 568
Related Papers
Frailty in Older Adults: Evidence for a Phenotype
|The Journals of Gerontology Series A|2001|24.4k
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
|New England Journal of Medicine|2010|5.5k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k